San Diego, September 7, 2023 – Shoreline Biosciences, Inc., a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNKs) and macrophages (iMACs), today announced a major milestone in its patent litigation with Fate Therapeutics, Inc. and the Whitehead Institute in the U.S. District Court for the Southern District of California.
The district court granted Shoreline’s motion for summary judgement of non-infringement on all of Fate and Whitehead’s patent infringement claims, ruling that the Fate/Whitehead patents did not reach Shoreline’s use of iPSCs in its drug development programs as Fate and Whitehead had claimed.
Kleanthis G. Xanthopoulos, Ph.D., Shoreline’s Chairman and CEO, commented: “The district court’s ruling represents a complete victory against this meritless lawsuit, which wasted significant capital and resources. Fate and Whitehead tried to stretch patents about Somatic Cell Nuclear Transfer (SCNT) to cover iPSCs that Dr. Yamanaka invented and for which he won the Nobel Prize. The district court wisely rejected that claim. We are thrilled to have successfully defended against this lawsuit, and we remain committed to continuing to develop effective and differentiated cellular immunotherapies that have the potential to treat cancer and other serious diseases to help patients and save lives.”
The district court’s order can be accessed here.
Shoreline was represented by Morrison & Foerster (MoFo) in the patent infringement litigation. See also
https://www.mofo.com/resources/news/230831-mofo-wins-summary-judgment
About Shoreline Biosciences
Shoreline Biosciences is a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNKs) and macrophages (iMACs). The company’s cellular design and gene editing technologies are built on a unique understanding of iPSC differentiation, immune cell biology and premier gene editing tools such as SLEEK knock-in technology and access to AsCas12a, a high fidelity and high efficiency engineered CRISPR/CAS endonuclease. Shoreline’s allogeneic effector cells are designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company.
For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.
Investor Contact:
Amy Conrad
Juniper Point
858-366-3243
Media Contact:
David Schull
Russo Partners
David.Schull@russopartnersllc.com
212-845-4271
